Omega Diagnostics sees 'significant progress' in Covid-19 antibody test

Medical diagnostics company Omega said on Wednesday that the UK Rapid Test Consortium has made "significant progress" in developing a Covid-19 lateral flow antibody test that can be used by people in their homes.

As the lead party of the UK-RTC, Omega said its partner Abingdon Health had been developing a Covid-19 rapid test and made solid progress in just "a short period of time".

Omega stated its role as a member of the UK-RTC was unchanged and will provide volume manufacturing capacity of the test once design freeze has been attained by Abingdon.

Chief executive Colin King said: "I am really impressed with the progress Abingdon have made to date with the development in such a short period of time.

"Everyone is working extremely hard to deliver a high-quality product as soon as possible to help play a part in returning life back to more normal levels in the UK."

As of 1105 BST, Omega shares were down 1.76% at 69.75p.